Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

726.19 -9.01 (-1.23%)
Delayed Quote Updated: 11:34 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
66 67 Next >
News headline image
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs ↗
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy... 
Via Benzinga
News headline image
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts ↗
 
Via Benzinga
News headline image
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ↗
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today ↗
 
Via Benzinga
News headline image
Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
News headline image
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024 ↗
Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks. 
Via InvestorPlace
News headline image
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market ↗
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market. 
Via Benzinga
News headline image
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
2 Biotech Stocks to Buy in May ↗
You could buy these in any month, really. 
Via The Motley Fool
News headline image
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks ↗
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily
News headline image
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club ↗
Enthusiasm is growing for a looming approval in COPD treatment. 
Via Investor's Business Daily
News headline image
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
News headline image
Stock Split Watch: 3 Growth Stocks That Could Be Next ↗
Success has some downsides, including a much higher stock price. 
Via The Motley Fool
News headline image
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
What's Going On With FibroGen Stock Tuesday? ↗
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial... 
Via Benzinga
News headline image
FibroGen Stock Is Surging After The Bell: What's Going On? ↗
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease ↗
The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What's Going On With Biohaven Stock Wednesday? ↗
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates. 
Via Benzinga
News headline image
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
News headline image
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years ↗
It might not be too late to invest in these impressive growth stocks. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.